Literature DB >> 12908996

Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy.

James M Roberts1, Gail D Pearson, Jeffrey A Cutler, Marshall D Lindheimer.   

Abstract

A Working Group on Research in Hypertension in Pregnancy was recently convened by the National Heart Lung and Blood Institute to determine the state of knowledge in this area and suggest appropriate directions for research. Hypertensive disorders in pregnancy, especially preeclampsia, are a leading cause of maternal mortality worldwide and even in developed countries increase perinatal mortality five-fold. Much has been learned about preeclampsia but gaps in the knowledge necessary to direct therapeutic strategies remain. Oxidative stress is a biologically plausible contributor to the disorder that may be amenable to intervention. Hypertension that antedates pregnancy (chronic hypertension) bears many similarities to hypertension in nonpregnant women but the special setting of pregnancy demands information to guide evidence based therapy. The recommendations of the Working Group are to attempt a clinical trial of antioxidant therapy to prevent preeclampsia that is be complemented by mechanistic research to increase understanding of the genetics and pathogenesis of the disorder. For chronic hypertension clinical trials are recommended to direct choice of drugs, evaluate degree of control and assess implications to the mother and fetus. Recommendations to increase participation in this research are also presented.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12908996     DOI: 10.1081/PRG-120016792

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  52 in total

1.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

2.  Enhancement of trophoblast differentiation and survival by low molecular weight heparin requires heparin-binding EGF-like growth factor.

Authors:  Alan D Bolnick; Jay M Bolnick; Hamid-Reza Kohan-Ghadr; Brian A Kilburn; Omar J Pasalodos; Pankaj K Singhal; Jing Dai; Michael P Diamond; D Randall Armant; Sascha Drewlo
Journal:  Hum Reprod       Date:  2017-06-01       Impact factor: 6.918

3.  Uric acid inhibits placental system A amino acid uptake.

Authors:  S A Bainbridge; F von Versen-Höynck; J M Roberts
Journal:  Placenta       Date:  2008-12-05       Impact factor: 3.481

4.  Physical Activity During Pregnancy and Subsequent Risk of Preeclampsia and Gestational Hypertension: A Case Control Study.

Authors:  Cassandra N Spracklen; Kelli K Ryckman; Elizabeth W Triche; Audrey F Saftlas
Journal:  Matern Child Health J       Date:  2016-06

5.  Non-cardiac complications during pregnancy in women with isolated congenital pulmonary valvar stenosis.

Authors:  W Drenthen; P G Pieper; J W Roos-Hesselink; A C M Schmidt; B J M Mulder; A P J van Dijk; H W Vliegen; K M Sollie; A A Voors; T Ebels; D J van Veldhuisen
Journal:  Heart       Date:  2006-07-03       Impact factor: 5.994

6.  Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia.

Authors:  Caitlin J Smith; Audrey F Saftlas; Cassandra N Spracklen; Elizabeth W Triche; Andrew Bjonnes; Brendan Keating; Richa Saxena; Patrick J Breheny; Andrew T Dewan; Jennifer G Robinson; Josephine Hoh; Kelli K Ryckman
Journal:  Am J Hypertens       Date:  2015-05-23       Impact factor: 2.689

7.  Placental Nkx2-5 and target gene expression in early-onset and severe preeclampsia.

Authors:  Elena R Rivers; Anthony J Horton; Angela F Hawk; Elizabeth G Favre; Katherine M Senf; Paul J Nietert; Eugene Y Chang; Ann C Foley; Christopher J Robinson; Kyu-Ho Lee
Journal:  Hypertens Pregnancy       Date:  2014-07-02       Impact factor: 2.108

8.  An analysis of expectant management in women with early-onset preeclampsia in China.

Authors:  Q Chen; F Shen; Y F Gao; M Zhao
Journal:  J Hum Hypertens       Date:  2014-10-23       Impact factor: 3.012

9.  Offspring's blood pressure and metabolic phenotype after exposure to gestational hypertension in utero.

Authors:  Satu Miettola; Anna-Liisa Hartikainen; Marja Vääräsmäki; Aini Bloigu; Aimo Ruokonen; Marjo-Riitta Järvelin; Anneli Pouta
Journal:  Eur J Epidemiol       Date:  2013-01-25       Impact factor: 8.082

10.  Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia.

Authors:  Jose A Santiago-Font; Lorena M Amaral; Jessica Faulkner; Tarek Ibrahim; Venkata Ramana Vaka; Mark W Cunningham; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-09-14       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.